JPRN-UMIN000024816已完成2 期
A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601) - A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment (OLCSG1601)
Okayama Lung Cancer Study Group (OLCSG)0 个研究点目标入组 80 人开始时间: 2016年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) A case who has active double cancer. Even in case of metachronous double cancer (more than 5 years), patient with a history of chemotherapy or chest radiotherapy is excluded. (2) A case with severe drug allergy history. (3) Pregnant / lactating woman, a woman with an intention of pregnancy, a man with a partner who has an intention of pregnancy. (4) A case with severe complications such as the following. Active interstitial lung disease in chest X ray and CT Serious heart disease (difficult to control angina, myocardial infarction within 3 months, etc.) Diabetes mellitus difficult to control Serious infection Active hepatitis B, hepatitis C Other complications that are thought to have serious obstacles to the performance of treatment (5) A case with peripheral sensory neuropathy or peripheral motor neuropathy of more than grade 2. (6) A case that the doctor judged inappropriate.
研究者
相似试验
尚未招募
2 期
ANTS Trial (Australian Neoadjuvant Therapy Study for Non-small Cell Lung Cancer)ACTRN12608000061336Austin Health100
已完成
2 期
Multicenter randomized phase II study of cisplatin+pemetrexed+bevacizmab followed by maintenance pemetrexied with or without bevacizmab in patients chemoterapy-naive advanced non-squamous non-small cell lung cancer with wild type EGFR(TORG1321)JPRN-UMIN000010681Thoracic Oncology Tesearch Group108
进行中（未招募）
不适用
Randomized fase II trial: comparing Cisplatin, Paclitaxel and Gemcitabine vs. Cisplatin, Paclitaxel, Gemcitabine and Avastin in patients with unknown primary tumorsEUCTR2007-000663-18-DKRigshospitalet, Onkologisk Klinik120
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusEUCTR2019-000308-13-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)180
进行中（未招募）
1 期
Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virusOropharyngeal Squamous Cell CarcinomaMedDRA version: 20.1Level: LLTClassification code 10079785Term: Oropharyngeal squamous cell carcinoma stage IVSystem Organ Class: 100000004864EUCTR2019-000308-13-ITEuropean Organisation for Research and Treatment of Cancer (EORTC)180